Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.

Original languageEnglish (US)
Pages (from-to)234-237
Number of pages4
JournalCancer
Volume117
Issue number2
DOIs
StatePublished - Jan 15 2011

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia. / Tefferi, Ayalew.

In: Cancer, Vol. 117, No. 2, 15.01.2011, p. 234-237.

Research output: Contribution to journalArticle

@article{590826134e354b1b872ed72f47b79524,
title = "Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia",
abstract = "Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.",
author = "Ayalew Tefferi",
year = "2011",
month = "1",
day = "15",
doi = "10.1002/cncr.25600",
language = "English (US)",
volume = "117",
pages = "234--237",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia

AU - Tefferi, Ayalew

PY - 2011/1/15

Y1 - 2011/1/15

N2 - Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.

AB - Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.

UR - http://www.scopus.com/inward/record.url?scp=78650981668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650981668&partnerID=8YFLogxK

U2 - 10.1002/cncr.25600

DO - 10.1002/cncr.25600

M3 - Article

VL - 117

SP - 234

EP - 237

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -